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Blood pressureNa+-transport regulating mechanisms classically considered to reﬂect renal control of sodium homeostasis and
BP, i.e. aldosterone–mineralocorticoid receptors (MR)—epithelial sodium channels (ENaC)—Na+/K+-ATPase
have now been demonstrated to also be present in the central nervous system. This pathway is being regulated
independently of the peripheral/renal pathway and contributes to regulation of cerebrospinal ﬂuid [Na+] by the
choroid plexus, of brain tissue [Na+] by the ependyma and to neuronal responses to e.g. Na+ or angiotensin II.
Increases inCSF [Na+]by central infusionofNa+-rich aCSForbyhigh salt intake inDahl S or SHRcause sympatho-
excitation and hypertension. These responses appear to depend on activation of a CNS cascade starting with
aldosterone–MR–ENaC–“ouabain,” the latter lowering neuronal membrane potential leading to enhanced
angiotensin II release in e.g. the PVN. Speciﬁc CNS blockade of any of the steps in this cascade from aldosterone
synthase blockade to AT1-receptor blockade prevents the sympathetic hyperactivity and hypertension on high
salt intake, irrespectiveof thepresenceof a “salt-sensitive kidney.”Wepropose that in salt-sensitivehypertension
an increase in CSF [Na+] causes a local increase in aldosterone biosynthesis which activates an aldosterone
dependent neuromodulatory pathway which enhances activity of angiotensinergic sympatho-excitatory
pathways leading to hypertension.ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
High dietary salt intake is a major lifestyle factor contributing to
the progressive increase in blood pressure (BP) with aging in most
societies [1]. Salt-sensitivity of BP varies between populations and
both human and animal studies have demonstrated a major genetic
contribution to salt-sensitivity versus salt-resistance of BP [2]. Despite
extensive research efforts, the actual genetic and mechanistic
determinants of this paradigm remain elusive for both animal models
and humans. The slow progress on this major health issue may be
related—among others—to the nearly exclusive focus on the kidneys
as the cause of salt-sensitive hypertension. For genetically determined
salt-sensitivity, it is commonly assumed that intrinsic changes in renal
function lead to a defect in the kidneys' ability to excrete salt and to an
increase in BP until sodium balance is restored by enhanced pressure
natriuresis. In this concept, the hypertension is essential to restore
sodium balance. However, studies performed some decades ago [3–5]
demonstrated already that blockade of mechanisms leading to
sympathetic hyperactivity can prevent/reverse the hypertension in
e.g. Dahl salt-sensitive (S) rats on high salt intake without causing
edema or hypernatremia, indicating that the Dahl S kidney canmaintain sodium and water homeostasis without hypertension.
Hypertension associated with gain-of-function mutations in a major
Na+-transport regulating pathway, i.e. aldosterone–mineralocorticoid
receptor (MR)—epithelial sodium channels (ENaC)—Na+/K+-ATPase,
such as Liddle's syndrome [6,7] is classically attributed to enhanced
renal sodium re-absorption. In recent years it had become apparent
that this pathway is also present in the central nervous system (CNS)
andmay play a major role in the regulation of cerebrospinal (CSF) and
brain tissue [Na+]. The possible role for this CNS pathway in humans
with Liddle's syndromeor relevant animalmodels such as theNedd4-2
knockout mice [8] has not yet been studied. On the other hand, recent
studies by our and other groups have established that this Na+-
transport regulating pathway in the CNS plays an essential role in salt-
induced hypertension in animal models of salt-sensitive hypertension
such as Dahl S rats.
How can high salt intake activate CNS mechanisms leading to
hypertension? One possibility is sensing of the sodium load by the
kidneys which via the renal afferent nerves may activate CNS afferent
pathways and thereby CNS efferent mechanisms causing an increase
in BP. Recent studies support an alternative concept, i.e. that high salt
intake may be sensed by the CNS and the latter determines the extent
of the salt induced increase in BP (Fig. 1). In the present review we
will focus on factors contributing to the regulation of Na+-transport
and [Na+] in the CNS, in particular the role of the aldosterone–MR–
ENaC–Na+/K+ATPase pathway, and the critical role of this pathway
for salt-sensitive hypertension.
Fig. 1. Schematic outline of brain kidney interactions for high salt-induced hypertension.
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2.1. High salt intake and CSF [Na+]
In the presence of free water intake, food intake with high salt
content may cause small, transient increases in plasma [Na+], which
may be detectable depending on the timing and extent of water intake
and timing of blood sampling relative to the high salt intake [9–11].
High salt diet does not affect CSF [Na+] in “salt-resistant” rat strains
such as Wistar, WKY and Dahl R rats [11,12]. However, salt-sensitive
hypertension in e.g. Dahl S rats and SHR is associated with changes in
the relationship between plasma [Na+] and CSF [Na+]. Intravenous
administration of 22NaCl causes signiﬁcantly larger increases in CSF
and brain parenchyma [22Na] in Dahl S compared to R rats, consistent
with enhanced Na+-entry across the blood-brain and CSF brain
barriers in Dahl S rats [13]. On high salt intake, the extent of
this difference between S and R rats becomes more pronounced [13],
suggesting that Dahl S rats have less buffering capacity compared to
control rats. Indeed, on regular salt intake Dahl S and R rats
have similar CSF [Na+] [11,12], suggesting that in Dahl S enhanced
Na+-inﬂux is offset by enhanced efﬂux. In contrast, Nakamura and
Cowley [12] ﬁrst reported that high salt intake in Dahl S but not R rats
causes a persistent increase in CSF[Na+] by 4 mMwithin 3 days. More
recently we showed that the increase in CSF[Na+] on high salt intake
precedes the increase in BP and heart rate in both Dahl S and SHR [11].
These studies indicate that in Dahl S and SHR functional changes in
mechanisms regulating sodium transport across the blood–brain-
barrier cause an increase in CSF[Na+] on high salt intake, and the
increase is not secondary to effects of e.g. hypertension on the blood-
brain-barrier.
In the only study in humans, very high salt diet (16–18 g/
day, ∼280 mmol/24 h urine) for 7 days similarly increased CSF[Na+]
by 2–3 mM in subjects with salt-sensitive (n=8) and non-salt-
sensitive (n=7) hypertension compared to a low salt diet (1–3 g/day,
∼20 mmol/24 hr urine) [14].
2.2. Regulation of CSF[Na+]
Theepitheliumof the choroidplexus is themajor site for productionof
CSF, which is later absorbed by arachnoid granulations [15,16]. Net
transport of Na+ between plasma and CSF is a balance of Na+-inﬂux into
and efﬂux out of the choroid plexus cells which is accomplished by the
selectivedistribution andactivity of a variety of enzymesand transporters
on the apical (CSF-side) or the basolateral surface of the epithelial cells.Fig. 2 provides a schematic outline for 2 of these transporters, Na+/K+-
ATPase and ENaC. Na+/K+-ATPase is predominantly located on the
microvilli at the apical surface and provides the driving force for the
directional transport of Na+ into the CSF against the electrochemical
gradient [17–19]. Indeed, in Wistar rats intracerebroventricular (icv)
infusion of ouabain to inhibit Na+/K+-ATPase activity lowers CSF[Na+]
by 7 mM and in Dahl S rats on high salt diet icv infusion of antibody Fab
fragments to bind endogenous ouabain-like compounds (“ouabain”) and
thereby un-inhibit the enzyme, further increases CSF[Na+] by 6 mM [11].
A few years agowe demonstrated the presence of themRNA and protein
of theα,β andγENaC subunits in the epithelial cells of the choroid plexus
[20]. However, surprisingly, immunoreactivity was most prominent in
the apical membranes and cytoplasm, and at the subcellular level ∼35%
of αENaC and 15–20% of β and γENaC were in the apical microvilli, only
5–10% in the basolateral membranes and the remainder in the cyto-
plasm [21]. This distributionwould suggest that ENaCmight contribute to
Na+-inﬂux into the choroid plexus cells both from the CSF and the blood,
but inﬂux from the CSF may predominate. Indeed, consistent with the
apical location of most ENaC, in Wistar rats icv infusion of the ENaC
blocker, benzamil, signiﬁcantly increases CSF[Na+] by 8 mM [22]
presumably reﬂecting inhibition of Na+-transport from the CSF back
into the choroid plexus cells. Moreover, icv infusion of Na+-rich CSF
increases α and βENaC at the apical membrane of the choroid plexus,
presumably to increase Na+-transport from the CSF into the epithelial
cells of the choroidplexus [22]. Thedual locationof ENaCatboth the apical
and basolateral membrane of the choroid plexus cells is quite unique
compared to the renal tubule epithelial cells where there is strict uni-
directional Na+-transport through ENaC at the luminal side andNa+/K+-
ATPase at the basolateral membrane [23]. In the brain, regulation of CSF
and brain interstitium [Na+] cannot depend on parallel changes in water
transport, andmay requiremovement ofNa+via ENaC in either direction.
Regarding possible regulators of ENaC expression in the choroid
plexus, bothmRNA and protein for MR are present in epithelial cells of
the choroid plexus [20]. Effects of aldosterone on ENaC expression in
the brain have not yet been studied. However, central infusion of the
MR blocker, spironolactone, prevents the increase in immunoreactiv-
ity but not in mRNA for βENaC by Na+-rich CSF in the choroid plexus
[22], consistent with post-transcriptional regulation via MR as one of
the mechanisms regulating ENaC expression in the choroid plexus.
The actual mechanisms contributing to the increases in CSF[Na+] in
Dahl S and SHR on high salt diet have not yet been elucidated. Recently
we showed thatwhen studied in vitro, the choroid plexus of Dahl S vs. R
rats on regular salt diet appears to exhibit enhanced Na+-inﬂux and
efﬂux, associated with higher ENaC expression at the apical membrane
in Dahl S [21]. The lattermay enhanceNa+ inﬂux from the CSF back into
the choroid plexus and maintain a normal CSF[Na+] in S rats despite
higher Na+-transport across the choroid plexus into the CSF in Dahl S
rats. On high salt diet, the higher ENaC expression in Dahl S rats
persisted, but did not increase further as onemay anticipate in response
to the higher CSF[Na+] onhigh salt diet. On the other hand, high salt diet
increased intracellular [Na+] in the choroid plexus of R rats by 30% and
markedly decreased the ouabain sensitive component of Na+-efﬂux.
This decrease in Na+/K+-ATPase activity may be a mechanism to
prevent an increase in CSF[Na+]. The mechanisms responsible for this
decrease in activity still need to be explored and these studies may lead
to new insights into salt resistance. In contrast to Dahl R, in Dahl S high
salt diet does not inhibit ouabain-dependent Na+-transport. A persis-
tent high activity of the pump may increase CSF[Na+], resulting in
increased release of “ouabain” [24] to inhibit the pump activity and to
blunt the increase in CSF[Na+] [11]. Alternatively, CSF[Na+] may
increase through other mechanisms, but the resultant increase in
“ouabain” would also inhibit the pump, and enhance Na+/K+-ATPase
expression through negative feedbackmechanisms [25,26]. In vitro, any
endogenous “ouabain” dissociates from the enzyme during pre-
incubation [26], thereby exposing uninhibited pump activity. Altogeth-
er, as schematically summarized in Fig. 3, our studies demonstrate
Fig. 2. Schematic outline of the possible role of ENaC in Na+-transport across the choroid plexus and ependyma inWistar rats. Under physiological conditions, ENaC predominates at the
apical membrane of the choroid plexus and ependymal cells, presumably leading to net Na+-transport from the CSF into choroid plexus epithelial cells or into brain tissue (A). An increase
in CSF [Na+] byNa+-rich aCSF increases ENaC at the apicalmembrane of the choroid plexus, presumably to increase Na+-transport from the CSF into epithelial cells of the choroid plexus.
ENaC also increases at the basolateralmembraneof the ependyma, presumably to allowmoreNa+out of the brain tissue back into the CSF (B). Icv infusion ofNa+-rich aCSF also increases
endogenous “ouabain” to inhibit Napumpactivity at the apicalmembraneof the choroidplexus cells to inhibit (further)Na+-transport into theCSF (B). For speciﬁc data, see reference [22].
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rats that may contribute to the increase in CSF[Na+] in this strain on a
high salt diet. Further studies are needed to elucidate the possible
mediators of this abnormal Na+-transport. Regarding possible other
regulators of Na+-transport in the CNS, the role of adducin for salt-
sensitive hypertension in, e.g. Dahl S or Milan hypertensive rats has not
yet been assessed. Adducin is a ubiquitously expressed tetrameric
cytoskeletal protein composed of α/β or α/γ heterodimers and
stimulates Na+/K+-ATPase activity by increasing the apparent ATP
afﬁnity to Na+/K+-ATPase [27]. Besides being present in the kidney, all
three adducin subunits are also present in the hypothalamus [28].
Whether adducin regulatesNa+/K+-ATPase in the CNShas not yet been
studied, but this is possible considering that α-adducin co-immuno-
precipitates with α2/3 Na+/K+-ATPase from neurons of both SHR and
WKY rats [28].
2.3. Sympatho excitatory and pressor responses to CSF[Na+]
Neurons in circumventricular organs exposed to blood and CSF such
as the area postrema, subfornical organ and the organum vasculosum
laminae terminalis, as well as neurons in the median preoptic nucleusand paraventricular nucleus exposed to brain tissue [Na+] are sodium
sensitive [29–31]. Small increases inCSF[Na+] by≥2 mMare sufﬁcient to
increase theﬁring rate of neurons in e.g. the paraventricular nucleus [32].
Sympatho-excitatory and pressor responses to icv infusion of Na+-rich
CSF can be readily induced in a variety of species, including rats andmice
[33–36]. These responses depend on the Na+-ion, and not on changes in
osmolarity or CSF[CI-] [31,33,34]. In normotensive rat strains, chronic icv
infusion of Na+-rich CSF that increases CSF[Na+] by 4–6 mM enhances
sympathetic drive, blunts arterial baroreﬂex function, and increases BPby
15–25 mm Hg [34,36,37].
Dahl S and SHR on regular salt diet exhibit enhanced neuronal
responses to increases in CSF[Na+]. Sympatho-excitatory and pressor
responses to a brief icv infusion of Na+-rich CSF are ∼2-fold larger in
SHR vs. WKY [33] and in Dahl S vs. R or Wistar rats [38,39]. Similarly,
chronic icv infusion of Na+-rich CSF causes marked sympatho-
excitation and hypertension in Dahl S rats, but only mild changes in
Dahl R rats [38]. Thus the general CNS phenotype induced by high salt
intake inDahl S and SHRcan be reproducedby increasingCSF[Na+]with
infusion of Na+-rich CSF. The actual genetic variants and mechanisms
contributing to the enhanced sympatho-excitatory and pressor
responses to an increase in CSF[Na+] in Dahl S are still unclear. Studies
Fig. 3. Schematic outline of Na+-transport across the choroid plexus of Dahl S and R rats on regular and high salt diet. Dahl S rats on regular salt diet exhibit enhancedNa+-transport across the
choroid plexus. Higher apical ENaC expression leads to enhanced Na+-inﬂux from the CSF back into the choroid plexus to maintain a normal CSF [Na+] (A). On high salt diet, Na+ -transport
across the choroid plexus further increases in S rats but apical ENaC expression does not further increase and CSF [Na+] increases. Apical Na+ pump activity persists in S rats, but release of
“ouabain” inhibitsNa+pumpactivity and attenuates the increase inCSF [Na+] in S rats (B). In contrast, apicalNa+pumpactivity decreases inR ratswhichmayprevent an increase inCSF [Na+].
For speciﬁc data, see reference [21].
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onC10QTL2 [40] andon chromosome13 [41] contribute to this neuronal
hyper-responsiveness and/or enable expression of genetic variants on
other loci.
3. Central mechanisms mediating pressor responses to CSF[Na+]
Acute increases in [Na+] in the CSF or in nuclei such as the
paraventricular nucleus appear to increase sympathetic activity and
BP primarily by local angiotensin II release [42], and can be prevented
by central angiotensin II blockade [37,43]. AT1-receptor blockade in
the subfornical organ [44], median preoptic nucleus [45] or in the
paraventricular nucleus [31] prevents the pressor responses to Na+-
rich CSF. Considering that the subfornical organ and median preoptic
nucleus have extensive connections to the paraventricular nucleus
[46] and that these connections use angiotensin II as a neurotrans-
mitter [47,48], one may consider that increases in CSF[Na+] primarily
excite Na+-sensitive nuclei in the lamina terminalis, i.e. the
subfornical organ and median preoptic nucleus and this increasedneuronal activity is being relayed to the paraventricular nucleus via
angiotensin II release causing local AT1-receptor stimulation. The
latter may excite subpopulations of neurons in the paraventricular
nucleus innervating presympathetic neurons in the rostral ventrolat-
eral medulla and/or spinally projecting neurons [49], thereby
increasing sympathetic activity, BP and heart rate [50]. How an
increase in CSF[Na+] is sensed and causes angiotensin II release has
not yet been resolved (for review see Orlov and Morgin [51]).
Activation of Nax channels in circumventricular organs such as the
SFO may play a role. These channels have been shown to regulate salt
appetite [52,53], but their possible role in BP regulation has not yet
been studied. Angiotensin II release shows calcium dependency [54],
and intracellular [Na+] may sufﬁciently increase to promote reverse
operation of the Na+/Ca2+ exchanger [55,56], and increase intracel-
lular [Ca2+] in response to higher CSF[Na+].
We have provided accumulating evidence for the novel concept that
a chronic increase in CSF[Na+] (1) activates a CNS neuromodulatory
pathway involving locally produced aldosterone, which via MR and
ENaC increases “ouabain’ production and release, and (2) activation of
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tensinergic pathways and via AT1-receptor stimulation causes sym-
patho-excitation and hypertension.
3.1. Aldosterone–MR–ENaC–“ouabain” in the hypothalamus
Aldosterone acting in the CNS may be either circulation derived
[57,58], or locally synthesized de novo from cholesterol or by
conversion of circulating steroid precursors [59]. Whether physiolog-
ically relevant synthesis of aldosterone occurs in the brain is still a
topic of debate (e.g. recent review by Geerling and Loewy, [60]). There
is extensive evidence for the presence of enzymes involved in
steroidogenesis in many parts of the CNS [60–63]. In rats, the brain
is a major extra-adrenal site of P-450 11β-hydroxylase (CYP11B1)
which converts 11-deoxycorticosterone (DOC) to corticosterone, and
P-450 aldosterone synthase (CYP11B2) which catalyses the steps
between DOC and aldosterone [63]. Expression levels for CYP11B2
mRNA in the whole hypothalamus [64,65] or in speciﬁc nuclei such as
the supraoptic and paraventricular nuclei [22] are several fold lower
than the levels in the adrenal gland. There is recent, indirect evidence
that these low mRNA levels indeed translate into actual enzymatic
activity (see 4). MR and the enzyme 11β-hydroxysteroid dehydroge-
nase type 2 (11β-HSD-2), which confers aldosterone speciﬁcity to the
otherwise non-selective MR, are present in the hypothalamus [65]
and in speciﬁc nuclei such as the supraoptic and paraventricular
nuclei [20,22,66]. Hypothalamic nuclei also express ENaC, and
immunoreactivity for ENaC subunits largely parallels MR expression,
mainly in neurons as assessed by double-staining with neuron-
speciﬁc nuclear protein, Neu N [20]. Magnocellular neurons in the
supraoptic and paraventricular nuclei are strongly positive both for
mRNA by in situ hybridization [22] and for protein by immunohis-
tochemistry [20], whereas the parvocellular neurons in the paraven-
tricular nucleus show minimal expression [20,22]. Finally, expression
for other ENaC regulatory genes, such as Sgk1 and Nedd4L has also
been demonstrated [22].
High levels of “ouabain” have been detected in the hypothalamus
and pituitary [67–69]. Immunoreactive neurons are particularly
localized in the magnocellular supraoptic and paraventricular nuclei
[70–73], but dense immunoreactivity was also reported in the
subfornical organ and median preoptic nucleus [71–73]. In in vitro
cultures, rat fetal hypothalamic, but not cortical cells secrete a Na+/K+-
ATPase inhibitor [74], consistent with the concept that the hypothal-
amus, and speciﬁcally magnocellular neurons may produce and release
a neurosteroid, “ouabain.” The chemical structure(s) of endogenous
ouabain-like compounds is still being debated [75,76]. One of the
inhibitors of the Na+, K+-ATPase enzyme appears to be a steroid closely
related to ouabain [67,77,78]. Kawamira et al. [79] concluded that this
endogenous compound in the bovine hypothalamus indeed is ouabain,
but may exist in vivo in complex with inorganic elements. Little is
known regarding the enzymes involved in the synthesis of “ouabain.”
Using microarray analysis, Q-RTPCR and gene silencing by siRNAs, the
group of Haupert reported marked up-regulation of genes coding for
P450 side chain cleavage and Δ5-3β-HSDΔ5-Δ4-isomerase enzymes in
the hypothalamus of hypertensive vs. normotensiveMilan rats, and that
knockdown of the latter gene decreased production of “ouabain” from
neural tissue [80].
The brain is very sensitive to the effects of ouabain as neurons express
the α3-isoform, the most ouabain-sensitive isoform of the α-subunits
[81]. CSF concentrations for “ouabain” have been reported in the 1–2 nM
range [82], which are close to the IC50 of 7 nM for the α3-isoform [83].
Effects of Na+ rich aCSF or high salt diet on CSF[“ouabain”] have not yet
been reported. Icv or intra-nuclear administration of ouabain in nuclei
such as themedian preoptic nucleus [84], paraventricular nucleus [31] or
the rostral ventrolateral medulla [85] causes dose-related increases in
sympathetic nerve activity, BP and heart rate. The sympatho-excitation
induced by ouabain infused either icv or directly into the paraventricularnucleus appears to depend on angiotensin II release, since it can be
blocked by an AT1-receptor blocker [31,86,87] and is absent in transgenic
rats without a functional brain renin–angiotensin system [88]. Assess-
mentof the functional roleof endogenous “ouabain” is possibleby speciﬁc
inhibition of its binding to the enzyme by antibody Fab fragments with a
high afﬁnity for ouabain and “ouabain” [89,90]. Fab fragments block in
vitro theNa+,K+-ATPase inhibitory effects[90], and invivo the sympatho-
excitatory and pressor responses of ouabain or “ouabain” in the CNS [91].
These pressor responses appear not only due to direct arterial
vasoconstriction by sympathetic hyperactivity, but also may have a
major indirect component via release of marinobufagenin from the
adrenal cortex [92,93].
4. Aldosterone–“ouabain” pathway and
salt-sensitive hypertension
In normotensive Wistar rats, central infusion of aldosterone at low
rates increases hypothalamic “ouabain” content [94] and causes
sympatho-excitation and hypertension [94,95]. Small increases in CSF
[Na+] enhance these responses [94]. Central infusion of a MR
antagonist or of benzamil to block ENaC [96] prevent the increase in
hypothalamic “ouabain” and the hypertension, and central infusion of
“ouabain” binding Fab fragments prevents the hypertension [94,97–
99]. In parallel, we established that a chronic central infusion of Na+-
rich CSF increases hypothalamic aldosterone, corticosterone and
“ouabain” content [94,100,101]. Central blockade of MR or ENaC
prevents the increase in “ouabain” and BP [94,99,100]. Recently, we
showed that central infusion of an aldosterone synthase inhibitor
prevents the Na+-rich CSF induced increases in hypothalamic
aldosterone (but not corticosterone) content, and in sympathetic
activity and BP [101]. How and where in the hypothalamus an
increase in [Na+] may increase aldosterone production has not yet
been addressed. The increases in both corticosterone and aldosterone
may indicate activation of enzymes catalyzing early, rate-limiting
steps of steroidogenesis such as the steroidogenic acute regulatory
protein (StAR) or the cholesterol side-chain cleavage enzyme CYP11A
[102,103]. Similarly, the mechanisms mediating the increase in
“ouabain” production/secretion by aldosterone in the CNS appear to
involve ENaC [94,99], but otherwise are still unknown.
The ENaC blocker benzamil increases CSF[Na+] [see 2.2], but
prevents the increase in hypothalamic tissue[Na+] [22], consistent
with an important role of ENaC in the ependyma [20,22] in the active
transport of Na+ from the CSF into the brain tissue (see Fig. 2). If tissue
[Na+] is the initial stimulus in the pathways leading to aldosterone
production, then ENaCmay contribute to the activation of aldosterone
by CSF[Na+] as well as mediate the increase in “ouabain” production
by aldosterone. Benzamil should then prevent increases in both
aldosterone and “ouabain” in the hypothalamus in response to e.g. icv
infusion of Na+-rich aCSF or high salt intake in Dahl S rats. This still
needs to be explored.
If an increase in CSF[Na+] plays a major role in the hypertension
induced by high salt intake in Dahl S, one may expect that (1) Dahl S
on high salt show activation of the same CNS mechanisms as those
activated by central infusion of Na+-rich CSF, and (2) blockade of
these mechanisms prevents the salt-induced hypertension in Dahl S.
In Dahl S, high salt intake signiﬁcantly increases hypothalamic
aldosterone content by ∼35%, and causes a modest, ∼20% increase
in hypothalamic corticosterone. Interestingly, salt-resistant rats show
decreases in both steroids on high vs. regular salt intake [104]. Central
infusion of an aldosterone synthase inhibitor prevents the increase in
hypothalamic aldosterone and partially (50–70%) prevents the salt-
induced hypertension. In contrast, central infusion of the steroid
synthase 3β-HSD inhibitor trilostane, which blocks synthesis of both
corticosterone and aldosterone, fully prevents the hypertension [57],
as does central infusion of a MR blocker [104,105]. These ﬁndings
indicate that central MR activation indeed mediates the salt-induced
Fig. 4. Schematic outline of CNS pathways activated by an increase in CSF[Na+]. Acutely,
CSF[Na+] activates sympatho-excitatory angiotensinergic pathwaysoriginating in theSFO.
Chronically, CSF[Na+] via the SFO also activates the aldosterone–“ouabain” neuromodu-
latory pathway, which then maintains enhanced angiotensinergic activity in e.g. the
paraventricular nucleus. As an example of this dual activation, central infusion of an
aldosterone synthase inhibitor does not prevent the initial pressor response to central
infusion of Na+-rich CSF, but fully prevents the chronic hypertension [ref [101]].
CSF, cerebrospinal ﬂuid; SFO, subfornical organ; SON, supraoptic nucleus; PVN,
paraventricular nucleus; MR, mineralocorticoid receptors; ENaC, epithelial sodium
channels.
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e.g. corticosterone or 11β-HSD-2 activity may contribute as well
[105]. Alternatively, higher doses of the aldosterone synthase blocker
may be needed to cause more complete blockade of aldosterone
production and release in speciﬁc brain nuclei of Dahl S. Consistent
with our ﬁndings, Gomez-Sanchez et al. [65] recently reported that in
adult Dahl S rats central infusion of the same aldosterone synthase
inhibitor prevents the further increase in BP in response to 0.9% saline
replacing water to drink.
Effects of Na+-rich aCSF and of aldosterone in Wistar rats can be
prevented by central infusion of benzamil blocking ENaC. Similarly, in
Dahl S icv infusion of benzamil prevents the high salt-induced increases
in hypothalamic “ouabain” content and in BP [24,106,107]. However,
whereas in Wistar rats Na+-rich CSF does not appear to affect ENaC
expression and may decrease one regulator of channel activity, Sgk1, in
the supraoptic and paraventricular nuclei [22], high salt intake increases
mRNA expression of α, β and γ ENaC, as well as Sgk1 in the supraoptic
nucleus of Dahl S, but not R rats (unpublished data). Assessment of
protein by western blot and immunohistochemistry is presently in
progress.
Similar to central infusions of aldosterone or of Na+-rich CSF, high
salt intake increases hypothalamic “ouabain” content in Dahl S and
SHR [89,108]. Moreover, central infusion of Fab fragments to bind
“ouabain” prevents the salt-induced sympatho-excitation, as well as
the hypertension, indicating that centrally released “ouabain” also
plays a major role in the salt-induced hypertension in these strains
[109–113].
Altogether, the above ﬁndings indicate that the aldosterone-MR-
ENaC “ouabain” pathway similarly mediates the sympatho-excitation
and hypertension induced by central infusion of Na+-rich CSF and by
high salt intake in Dahl S and SHR, supporting the concept that the
increase in CSF[Na+] by high salt intake in these strains also activates
this pathway. Two differences are apparent between the responses of
Dahl S to high salt diet and the responses ofWistar rats to icv infusion of
Na+-rich CSF which may contribute to enhanced effectiveness of this
activation by CSF[Na+] in Dahl S. Firstly, in Dahl S rats theMR activation
appears to depend on aldosterone aswell as other factors, and secondly
ENaC activation in the supraoptic nucleus of Dahl S rats may contribute
to enhanced responses, possibly by increasing “ouabain” release.
Consistent with the latter, a 2-week central infusion of aldosterone
increases markedly hypothalamic “ouabain”, sympatho-excitation and
BP in Dahl S, but causes only minor increases in Dahl R or Wistar rats
[97]. Responses to ouabain or angiotensin II either icv or in the
paraventricular nucleus are not enhanced in S vs. R rats [38,41],
indicating that responses downstream to “ouabain” are similar in S and
R and do not contribute to the enhanced responses to CSF[Na+] and
aldosterone.
5. Conclusion
We postulate that the aldosterone–“ouabain” neuro-modulatory
pathway, as shown in Fig. 4, reﬂects the concept initially proposed by
Nobel Prize winner Paul Greengard [114] of slow synaptic transmission
controlling effectiveness of fast-synaptic transmission, i.e. “ouabain”
inhibits neuronal Na+K+-ATPase and thereby lowers the membrane
potential and increases intracellular calcium.As a result,more excitatory
impulses reach threshold and ﬁring rates of these neurons increase. For
example, a subpressor dose of aldosterone or ouabain in the
paraventricular nucleus increases BP and HR responses to Na+-rich
CSF by 50–100% [31]. Sympatho-excitatory and pressor responses to an
increase in CSF[Na+] are primarily mediated via angiotensinergic
sympatho-excitatory pathways [31,86] from the forebrain to the
brainstem. During chronic increases in CSF[Na+] the effectiveness of
this pathway appears to become dependent on activation of slow
synaptic transmission, i.e. aldosterone–“ouabain” neuromodulation.
This concept is not unique for CNS activation by high salt intake. Forexample, chronic sympathetic hyperactivity in heart failure also appears
to depend on activation of this neuromodulatory pathway [115],
possibly through initial activation of the subfornical organ by circulating
angiotensin II [116,117].
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